--(BUSINESS WIRE)-- California Healthcare Institute:
David Gollaher, Ph.D., CHI President and CEO
Simon Goodall, The Boston Consulting Group Partner and Managing Director
In CHI’s most recent podcast series, Gollaher and Goodall discuss the findings of a recent CHI report: “Competitiveness and Regulation: The FDA and the Future of America’s Biomedical Industry.”
In recent years, there has been a dramatic shift of clinical trials and product launches by U.S. firms to Europe. Inefficiency at the FDA has led to American inventions being made available to patients and physicians in other countries first. This has also pushed jobs and revenues offshore, helping competitive nations gain experience in scaling up new biopharmaceutical and medical technology products. Importantly, though, patients are losing access to cutting-edge treatments.
|WHEN:||Monday, June 20, 2011|
CHI represents more than 250 leading biotechnology, medical device, diagnostics and pharmaceutical companies, and public and private academic biomedical research organizations. CHI’s mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. CHI’s website is www.chi.org. Follow us on Twitter @calhealthcare and Facebook.
California Healthcare Institute
KEYWORDS: United States North America California
INDUSTRY KEYWORDS: Health Biotechnology Hospitals Pharmaceutical Research FDA Science